Puma Biotechnology Inc (NASDAQ:PBYI) Valuation According To Analysts

Cornelia Mascio
Mag 6, 2017

Stifel Nicolaus reiterated a "buy" rating and set a $88.00 target price on shares of Puma Biotechnology in a research report on Wednesday, April 19th. They now have a $88.00 target price on the biopharmaceutical company's stock. Analysts have a mean recommendation of 1.70 on this stock (A rating of less than 2 means buy, "hold" within the 3 range, "sell" within the 4 range, and "strong sell" within the 5 range). Credit Suisse Group AG reiterated an outperform rating and issued a $58.00 price target on shares of Puma Biotechnology in a research note on Tuesday, April 18th. Royal Bank of Canada restated a "sector perform" rating and issued a $17.00 target price (down from $48.00) on shares of Puma Biotechnology in a research note on Thursday, March 2nd. Citigroup Inc reiterated a "buy" rating and issued a $88.00 price objective on shares of Puma Biotechnology in a research report on Saturday, March 4th. Finally, Zacks Investment Research lowered shares of Puma Biotechnology from a buy rating to a hold rating in a research note on Tuesday, January 10th.

Among 15 analysts covering General Growth Properties (NYSE:GGP), 9 have Buy rating, 0 Sell and 6 Hold. Ghost Tree Capital Llc acquired 50,000 shares as Puma Biotechnology Inc (Call) (PBYI)'s stock declined 52.17%.

Puma Biotechnology, Inc. (NASDAQ:PBYI) yearly performance is 44.87%. The company's market capitalization is $237.10 billion with the total outstanding shares of 9.95 billion. Puma Biotechnology Inc has a one year low of $19.74 and a one year high of $73.27.

The stock's 50 day moving average is 38.32 and its 200 day moving average is 38.01.

Puma Biotechnology (NYSE:PBYI) opened at 36.55 on Wednesday. The consensus recommendation by Thomson Reuters analysts is Outperform and their mean rating for the stock is 2.11 on scale of 1-5. On average, equities analysts expect that Puma Biotechnology Inc will post ($8.44) earnings per share for the current fiscal year. If you are viewing this report on another publication, it was illegally stolen and reposted in violation of worldwide copyright legislation. The correct version of this report can be read at https://www.themarketsdaily.com/2017/05/04/nj-state-employees-deferred-compensation-plan-has-341000-position-in-puma-biotechnology-inc-pbyi.html.

Several other hedge funds have also recently modified their holdings of the company.

Ghost Tree Capital Llc decreased Zogenix Inc stake by 100,000 shares to 225,000 valued at $2.73M in 2016Q4. UBS Asset Management Americas Inc. now owns 12,891 shares of the biopharmaceutical company's stock valued at $864,000 after buying an additional 300 shares during the period. California State Teachers Retirement System increased its stake in shares of Puma Biotechnology by 1.0% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 639,937 shares of the biopharmaceutical company's stock worth $42,908,000 after buying an additional 57,373 shares during the period. Franklin Street Advisors Inc. Jana Partners LLC bought a new position in Puma Biotechnology during the third quarter valued at $5,101,000. NC now owns 30,000 shares of the biopharmaceutical company's stock valued at $1,116,000 after buying an additional 1,000 shares during the period. Tower Research Capital LLC TRC boosted its position in shares of Puma Biotechnology by 253.3% in the third quarter. Finally, Traynor Capital Management Inc. boosted its position in shares of Puma Biotechnology by 27.1% in the third quarter. Traynor Capital Management Inc. now owns 10,972 shares of the biopharmaceutical company's stock worth $468,000 after buying an additional 2,341 shares during the last quarter.

Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.

Altre relazioniGrafFiotech

Discuti questo articolo

Segui i nostri GIORNALE